MET and non-small cell lung carcinoma: Crizotinib is an ALK, ROS‐1 and MET tyrosine kinase‐inhibitor that can be administered orally, and has shown >60% overall response rates in heavily pretreated patients with ALK‐positive NSCLC in single‐arm phase I and phase II trials.61, 68 Crizotinib led to significantly higher response rates and longer PFS as compared to conventional chemotherapy as second‐line treatment, and also compared to platinum/pemetrexed chemotherapy in untreated advanced NSCLC featuring ALK‐rearrangement.